FC
RXRX icon

Financial Consulate’s Recursion Pharmaceuticals RXRX Stock Holding History

Financial Consulate’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53K Hold
418
– – ﹤0.01% 1079
2026
Q1 		$1.28K Hold
418
– – ﹤0.01% 1067
2025
Q4 		$1.71K Hold
418
– – ﹤0.01% 922
2025
Q3 		$2.04K Buy
+418
New +$2.19K ﹤0.01% 777

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Financial Consulate's RXRX Position: Q2 2026 in Review

Financial Consulate held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 418 shares worth $1.53K. The position accounts for ﹤0.01% of the portfolio, ranked #1079.

Financial Consulate first reported a position in RXRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.04K in Q3 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Financial Consulate held 418 shares of Recursion Pharmaceuticals worth $1.53K as of Q2 2026.
  • Financial Consulate left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Financial Consulate's portfolio in Q2 2026, its #1079 holding.
  • Financial Consulate first reported a position in Recursion Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Financial Consulate's Recursion Pharmaceuticals position peaked at $2.04K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.